Gain Therapeutics Is A Biotechnology Company Dedicated To Discovering And Developing Innovativeallosteric Small Moleculetherapies For Neurodegenerativediseasesraregenetic Disordersand Cancerthecompany Utilizes Its Proprietary Magellana C Drug Discovery Platformwhich Combines Ai Supported Structural Biology And Advanced Modeling Techniques To Identify Novel Allosteric Binding Sites On Proteins Associated With Various Diseases Themagellana C Platform Enables Thediscovery Of Small Molecules That Can Modulateprotein Function In Multiplewaysaddressing High Unmet Medical Needsgain Therapeutics Is Advancing Its Clinical Stageproductgt 02287Which Targets Gba1 Associated Parkinsonaes Diseaseand Is Currently In A Phase1 Clinical Trialthecompany Also Has A Pipelinethat Includes Programs For Gaucher Diseasedementia With Lewy Bodiesand Alzheimeraes Diseasewith Potential Applications In Oncologygain Therapeutics Aims To Improvepatient Quality Of Lifethrough Its Focus On Diseasemodifying Therapies That Address Theunderlying Causes Of Complex Diseases
